Precision Biosciences Inc  (DTIL)
Other Ticker:  
Price: $13.2900 $1.12 9.203%
Day's High: $13.429 Week Perf: 12.15 %
Day's Low: $ 12.00 30 Day Perf: 23.06 %
Volume (M): 72 52 Wk High: $ 36.15
Volume (M$): $ 954 52 Wk Avg: $16.71
Open: $12.12 52 Wk Low: $8.25

 Market Capitalization (Millions $) 1,531
 Shares Outstanding (Millions) 115
 Employees -
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -90
 Capital Exp. (TTM) (Millions $) 3

Precision Biosciences Inc
Precision Biosciences Inc. is a biotechnology company founded in 2006 with headquarters in Durham, North Carolina. The company is focused on developing genome editing technologies that enable the precise modification of genes. Precision Biosciences utilizes its proprietary ARCUS Genome Editing technology, which is based on a naturally occurring enzyme called the homing endonuclease I-CreI. This technology allows for modifications in a wide range of cell types, including difficult-to-edit cells such as stem cells.

The company primarily aims to address genetic disorders and improve the development of cell and gene therapies. Precision Biosciences has collaborations with multiple pharmaceutical and biotechnology companies to develop and commercialize therapeutic products based on its genome editing platform. The company's lead product candidate, PBCAR0191, is a CD19-targeted CAR T-cell therapy being developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL).

Precision Biosciences also has a diverse pipeline of other genome editing programs targeting various diseases, including genetic diseases, cancer, and infectious diseases. The company has established partnerships with other companies in the field to leverage its genome editing technology for agricultural applications and sustainable food production.

In summary, Precision Biosciences Inc. is a biotechnology company working on developing precise and versatile genome editing technologies to address genetic disorders, improve cell and gene therapies, and explore other applications in agriculture and food production.

   Company Address: 302 East Pettigrew St. Durham 27701 NC
   Company Phone Number: 314-5512   Stock Exchange / Ticker: NASDAQ DTIL
   DTIL is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Precision Biosciences Inc

Precision Biosciences Inc Surpasses Expectations with Remarkable Reduction in Shortfall Amidst Strong Financial Performance

Precision Biosciences Inc, a biotechnology and pharmaceutical company, has released its financial results for the quarter ended September 30, 2023. The company experienced a significant increase in revenue, bucking the trend observed in the industry, while also reducing its losses per share. This article will analyze the key financial facts from the report and provide an overview of Precision Biosciences' recent stock performance.
Revenue Growth and Loss Reduction:
Precision Biosciences reported a respectable revenue advance of 78.188% in its September 30, 2023 report, reaching $13.12 million. This remarkable growth supported the reduction of losses per share to $-0.07, compared to $-0.22 in the same quarter the previous year.

Precision Biosciences Inc

Precision Biosciences Skyrockets with a Staggering 418.037% Revenue Boost in Q2 2023

Precision Biosciences Inc, a biotechnology and pharmaceutical company, has shown promising results in its fiscal second quarter of 2023. Compared to the same quarter the previous year, the company managed to significantly reduce its loss per share from $-0.46 to $-0.10. Additionally, the earnings per share improved from $-0.23 in the preceding quarter.
One of the highlights for Precision Biosciences Inc in the second quarter of 2023 was the substantial growth in revenue. The company experienced a remarkable increase of 418.037%, with revenue reaching $19.79 million compared to $3.82 million in the same quarter a year before. Furthermore, sequentially, the revenue doubled by 125.387% from $8.78 million in the preceding quarter.

Precision Biosciences Inc

Precision Biosciences Inc. reports impressive 164.697% year-on-year revenue growth, reaching $8.78 million for Q1 2023

Precision Biosciences Inc recently announced a significant increase in revenue for the financial period ending March 31, 2023. The company reported a year-on-year revenue rise of 164.697% to $8.78 million, which is a significant increase from the preceding financial reporting period. However, despite the impressive revenue figures, the company suffered a loss of $-0.23 per share, which is up from the $-0.17 per share loss in the previous reporting period.
In addition to the increase in revenue, Precision Biosciences' first quarter 2023 earnings show an impressive net shortfall of $-25.060 million, which is a significant improvement from the $-28.168 million deficit reported in the same financial reporting period a year ago. The company is set to report its next financial numbers on August 07, 2023.


Precision Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com